KRYS Krystal Biotech Inc: Rasio total nilai perusahaan marang pendapatan

Krystal Biotech Inc (KRYS) - logo korporat

Krystal Biotech, Inc. (KRYS) has developed an innovative platform for the first skin gene therapy, capturing the niche for treating epidermolysis bullosa. The business model is based on massive scientific investments followed by a sharp reduction in production costs. The monopoly status of the drug Vyjuvek ensures lifelong patient loyalty. The price-to-sales multiple visualizes market expectations, where 17989.83 captures the current value of the indicator.

KRYS (Krystal Corp) riwayat Multiplikator EV/Sales saka 23.11.2025 nganti 20.11.2026

Rincian metrik keuangan lan pasar Krystal Corp (KRYS)

- rega lan prakiraan konsensus rega:
Pambiji fundamental perusahaan:Krystal Biotech, Inc. - KRYS
Barang unggulan Krystal Biotech Inc

The explosive sales growth of Krystal Biotech, Inc. (KRYS) revolutionary gene therapy necessitates a business valuation that accounts for net debt and cash. This indicator compares total enterprise value to annual revenue, allowing investors to distinguish fundamental undervaluation from stagnation, as clearly illustrated by the long-term EV/Revenue chart.